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ABSTRACT 
Aberrant expression of the homeobox (HOX) gene family of transcription factors 
has been implicated in the development of many different cancers, including breast.  The 
high ratio of homeobox 13 (HOXB13) to interleukin-17-β receptor (IL17BR) expression has 
been found to be associated with increased relapse, tumor aggressiveness, tamoxifen (TAM) 
treatment failure, and death in breast cancer patients.  For nearly a decade, HOXB13 has 
been known as an effective biomarker of TAM resistance (TAMR), however its role in the 
disease was unclear. 
Our recent studies established that HOXB13 overexpression promotes TAMR as 
well as stromal invasion and metastasis via interleukin-6 (IL6) upregulation due to increased 
signaling of its pathway and subsequent stromal-tumor crosstalk.  In order to identify other 
potential, targetable mechanisms of HOXB13-mediated TAMR, we used a two-pronged 
approach to our goal, the first, using microarray analysis to discover new targets associated 
with HOXB13-expression in our cell line models, and the second, to interrogate other 
aspects of the IL-6 pathway that can possibly be more accessible, more effective targets to 
inhibit HOXB13-mediated-TAMR. 
Although our microarray studies did not yield novel targets of HOXB13-expressing 
TAMR, investigating other aspects of IL6 action in our HOXB13-expressing cell line models 
via inhibition of these downstream effectors found the anti-IL6R antibody tocilizumab 
(TOC) to specifically inhibit HOXB13-expressing tumor growth both in vitro and in vivo, as 
well as abrogate the stromal desmoplastic response typical of our HOXB13-overexpressing 
xenografts and of aggressive tumors. 
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These data suggest TOC to be a promising therapy able to specifically target 
HOXB13-expressing TAMR breast cancer, leading to more effective options for the 
treatment of TAMR, as well as a better understanding of the function and mechanism of the 
role of HOXB13 in this disease. 
 
Thesis Advisor 
Saraswati Sukumar, Ph.D. 
 
Thesis Committee 
Kenneth Kinzler, Ph.D. 
Srinivasan Yegnasubramanian, M.D., Ph.D. 













	   iv 
ACKNOWLEDGEMENTS 
 First, I would like to give my deep appreciation to my thesis advisor, Dr. Sara 
Sukumar.  I was drawn to her work and lab because of the knowledge, hard work, dedication, 
and passion she has for the study of breast cancer; upon my rotation, I felt that I had found 
my lab-home and I am so honored to have had the opportunity to learn from her.  In spite 
of the multiple changes, frustrating deviations, and failed experiments in my project, Sara has 
been such a patient, tough, yet kind, and stalwart guide in this journey, always trying to keep 
my head on straight and pushing me hard to keep my eyes on the prize.  Thank you so very 
much, Sara, for taking a chance on me, adopting me into this family, for being such a 
tremendous mentor throughout my graduate career. 
 Second, I would like to thank the members of the Sukumar Lab Family, past and 
present, for being such an amazing support system and a great group of friends.  Dr. (Mama) 
Mary Jo, thank you for all your wonderful, practical guidance and advice and for always 
keeping us “kids” in line.  Dr. Kideok Jin, for being my HOX/TAMR mentor, who helped 
us brainstorm my project into a successful thesis, for your constant help, insight, and advice, 
I am truly grateful. Master Sunju Park, thank you for your help with my troublesome 
experiments.  “Mouse Whisperer” Dr. Preethi Korangath-Chandran, thank you for all your 
help with my animal studies.  Dr. Vanessa Merino, my 1M desk-mate, thank you for your 
kind, motherly concern, always feeding us (mostly chocolate), for making sure we take care 
of ourselves, for your advice.  Master Wei Wen Teo, my bench-mate, I am so thankful for 
your scholarly help, for our entertaining conversations, for always making us laugh so hard 
to the point where I had to write it down to remember.  Sean Soonweng Cho, thank you for 
all the bioinformatics help, not to mention all the gchats, pop culture references, laughs, 
food, and fun.  Dr. Helen Sadik, thank you for being my lab-sister, for your help and advice 
	   v 
regarding my project and “next-step” in life.  Dr. Yolanda Hillocks-Foster and Dr. Talmesha 
Richards, my other lab-sisters, for your kind advice, support, and commiseration.  Sidra 
Hafeez and Arelí Lopez, thank you for all your kind help and for all the great conversations 
across the lab bench.  Thank you Dr. Liangfeng Han, Dr. Nguyen Nguyen, and soon-to-be-
Dr. Adam Diehl, for all the great talks, arguments/debates, and life-advice.  Dr. Nilay Shah, 
thank you for laying the groundwork of my project, and for your kindness.  Thank you to all 
my students for teaching me so much, maybe even more than I taught you.  Special thanks 
to the Breast Cancer Program Administration, for everything that they do – Cindy Morin, 
Kristen Wagner-Smith, Crystal Graham, Lexa Hartman, and Lauren Barrett. 
 I am so honored that the Cellular and Molecular Medicine Graduate Program took a 
chance on me; I couldn’t be a part of a more fitting, more wonderful program for what I 
wanted out of my Ph.D. experience.  Thank you so much to my “den mothers” Colleen 
Graham and Leslie Lichter, for their kindness, ever-ready support and advice, to the CMM 
Chairs Pierre Coulombe and Rajini Rao, for all their help, and my classmates from the class 
of 2008, for sharing their knowledge, struggles, and friendship. 
The guidance and help of my research mentors and co-workers from the numerous 
research experiences that came before became the stepping-stones on my way to Johns 
Hopkins.  Many thanks to Dr. J. Frederic Mushinski, Dr. Konrad Huppi, and my post-
baccalaureate lab at NCI, to Dr. Ken Kaye and Dr. Jocelyn Spragg at Harvard, and to Dr. 
George Teebor, Dr. Maria Ocampo-Hafalla, and Dr. Joel Oppenheim at NYU for all their 
support and mentorship.  I am also indebted to my undergraduate mentors at Mount Saint 
Mary’s College, especially to Dr. Tonia Symensma, Dr. Kelly Krass-McGoldrick, and to Dr. 
Sr. Annette Bower, CSJ, for their mentorship, friendship, and guidance.  Thank you three for 
being such wonderfully strong women-scientist role-models that I still look up to even now.  
	   vi 
Thank you Mr. Richard Beck at Bishop Amat Memorial High School, who made Honors 
and AP Biology so approachable and fascinating to me that I wanted to make a career out of 
its study. 
I would like to show my deep appreciation for my family and friends.  For my family 
back home in California, I knew it seemed crazy that I wanted to go to the east coast to 
study, but you all understood that this was an opportunity of a lifetime and thankfully gave 
me your blessings and encouragement.  To my Mom, Dad, brother Martin, Uncle Ed, Auntie 
Mae, the Macaso and Cruz families, thank you for believing in me, for your love, patience, 
never-ending support, and prayers.  Lolo Bert, Lola Angie, Lolo Monic, and Lola Asiang 
thank you for asking God to bless and help me, to keep me safe; thank you for your prayers.  
To my friends back home in California, thank you for your support and for always making 
time to visit me and catch up when I was home.  Thank you to my Midwest grad student 
friends Marianne Cabrera and Jeannine Abiva for commiserating with me, for all your love 
and support.  Thank you to my friends and family here on the east coast, for your love and 
support as well, especially Auntie Glory, the Monis families, and Jessica Llewellyn-Rami.  A 
super-special thanks to my wonderful friends here in Baltimore – Dr. Xiaohua Ni and family, 
Dr. Hee-sool Rho and Dr. Judit Ribas, Dr. Amarnath Mukharjee, Dr. Pierre Crassous and 
their families.  And a sincere thank you to Mark Castañares, who has been a wonderful 
support, role model, and partner to me this whole time. 
Without your mercy, love, and blessings, Heavenly Father, this all wouldn’t be 




	   vii 
TABLE OF CONTENTS 
Title           i 
Abstract          ii 
Acknowledgements         iii 
Table of Contents         vii 
List of Figures          ix 
List of Tables          xii 
Chapter 1:  Introduction        1 
1.1 Breast cancer and endocrine treatment     1 
1.2 Mechanisms of tamoxifen resistance (TAMR)    8 
1.3 HOX genes        9 
1.4 HOXB13 and TAMR       12 
Chapter 2:  Materials and Methods       15 
Chapter 3: HOXB13 mediates tamoxifen resistance and invasiveness in human breast 
cancer by inducing IL6 expression     22 
3.1  HOXB13 is overexpressed in primary ER-positive breast cancers and distant 
metastases        22 
3.2 HOXB13 overexpression promotes TAMR    22 
3.3 HOXB13 promotes stromal recruitment via IL6 upregulation  25 
3.4 IL6 is a direct transcriptional target of HOXB13   27 
3.5 The IL6 pathway is activated in HOXB13-expressing cells  31 
3.6 Rapamycin can inhibit proliferation of HOXB13-expressing breast cancer 
cells in vitro and in vivo       34 
Chapter 4:  Discovery of novel targets associated with HOXB13-expression 36 
	   viii 
4.1 Novel targets display correlation between mRNA expression and HOXB13-
expression        36 
4.2 Dickkopf-related protein 1 (DKK1)     41 
4.3 C-mer proto-oncogene tyrosine kinase (MERTK)   44 
4.4 The Cancer Genome Atlas (TCGA) database analysis for DKK1 and 
MERTK        47 
Chapter 5:  In vitro targeting of the IL-6 pathway in HOXB13-expressing 
breast cancer        48 
5.1 Fibroblast migration toward HOXB13-expressing cell line conditioned media 
is abrogated upon anti-IL-6R antibody Tocilizumab (TOC) treatment 48 
5.2 Niclosamide, inhibitor of STAT3 activation, is ineffective at inhibiting cell 
viability of HOXB13-overexpressing cells    52  
5.3 NVP-BEZ-235, PI3K inhibitor, is effective at inhibiting HOXB13-specific 
cell viability        52 
5.4 NVP-BEZ-235 is effective at specifically inhibiting phospho-Akt activation 
in HOXB13-expressing cells      57 
Chapter 6: In vivo targeting of the IL6 pathway in HOXB13-overexpressing breast cancer 
cell lines        60 
6.1 Tocilizumab (TOC) and BEZ235, both alone and in combination, inhibit 
HOXB13-overexpressing TAMR xenograft tumor growth  60 
Chapter 7: Discussion        68 
References          72 
Curriculum Vitae         78 
 
	   ix 
LIST OF FIGURES 
Figure 1.1 Stages of breast cancer progression     2 
Figure 1.2 Domain structures of ERα and ERβ    4 
Figure 1.3 Simplified model of the genomic and non-genomic modes of 
estrogen action        5 
Figure 1.4 Mechanism of action of estradiol/estrogen (E) compared to tamoxifen (T) at 
the level of transcriptional regulation     7 
Figure 1.5 Genomic organization and colinear expression patterns of Drosophila HOM 
and Human HOX genes      10 
Figure 1.6 Human HOX gene deregulation in cancer    11 
Figure 3.1 HOXB13 is overexpressed in primary ER-positive breast cancers and distant 
metastases        23 
Figure 3.2 HOXB13 overexpression promotes TAMR    24 
Figure 3.3 HOXB13 promotes stromal recruitment via IL6 upregulation  26 
Figure 3.4 IL6 is a direct transcriptional target of HOXB13   28 
Figure 3.5a IL6 signaling pathway       29 
Figure 3.5b-c IL6 signaling pathway activation in HOXB13-expressing breast cancer cells 
and recruited fibroblasts      32 
Figure 3.6 Rapamycin can inhibit proliferation of HOXB13-expressing breast cancer 
cells in vitro and in vivo       33 
Figure 4.1 Validation of HOXB13-expressing cell line model panels  37 
Figure 4.2 Differential expression observed after microarray analysis between BT474 
scramble control and the BT474 HOXB13-KD cell lines  38 
	   x 
Figure 4.3 Validation of target gene mRNA expression correlation with HOXB13-
expression        40 
Figure 4.4 DKK1 overexpression correlates with HOXB13-expression in CAMA1 and 
BT474 models        42 
Figure 4.5 Wnt ligand and co-receptor overexpression correlates with HOXB13-
expression        42 
Figure 4.6 Overexpression of Wnt target gene AXIN2 correlates with HOXB13-
expression; expression of Wnt target gene TWIST1 does not  43 
Figure 4.7 HOXB13 expression does not induce WNT signaling   43 
Figure 4.8 MERTK overexpression correlates with HOXB13-expression in CAMA1 
and BT474 models       45 
Figure 4.9 No trend of MERTK overexpression observed in primary breast cancers and 
distant metastases       45 
Figure 4.10 Diminutive change in DKK1 and MERTK mRNA expression between 
normal, tumor, and metastatic TCGA samples    46 
Figure 5.1 TOC does not significantly inhibit viability of HOXB13-overexpressing cells 
in culture        50 
Figure 5.2 TOC inhibits fibroblast migration toward HOXB13-expressing conditioned 
media         51 
Figure 5.3 Niclosamide does not significantly inhibit viability of HOXB13-
overexpressing cells in culture      53 
Figure 5.4 BEZ235 significantly inhibits viability of HOXB13-overexpressing cells in 
culture         54 
	   xi 
Figure 5.5 LY294002 does not significantly inhibit viability of HOXB13-overexpressing 
cells in culture        55 
Figure 5.6 PI-103 does not significantly inhibit viability of HOXB13-overexpressing 
cells in culture        56 
Figure 5.7 PI3K/Akt pathway activation in HOXB13-overexpressing cells via IL6 is 
inhibited by BEZ235 in a time-course manner    59 
Figure 6.1 Treatment of MCF7 HOXB13-overexpressing xenografts with TOC and 
BEZ, both alone and in combination inhibits palpable tumor growth 61 
Figure 6.2 Treatment of MCF7 HOXB13-overexpressing xenografts with TOC inhibits 
established tumor growth      63 
Figure 6.3 TOC treatment reversed stromal phenotype in MCF7 HOXB13-
overexpressing xenografts      65 
Figure 6.4 Treatment of HOXB13-expressing BT474-Scr xenografts with TOC alone, 
TAM alone, or in combination inhibits established tumor growth 66 
Figure 6.5 Treatment of HOXB13-knockdown BT474-HOXB13-KD xenografts with 









	   xii 
LIST OF TABLES 
Table 4.1 Top 5 upregulated and bottom 5 downregulated genes based on BT474 
HOXB13-KD cell line panel microarray analysis   39 
Table 5.1 Panel of IL6 pathway inhibitors tested against HOXB13-expressing cell line 







1.1 – Breast cancer and endocrine treatment 
Breast cancer is the second most common cancer among women in the United 
States, affecting one out of eight females (1) during their lifetime.  In 2013, an estimated 
232,340 new cases of invasive breast cancer were diagnosed, and during this time, almost 
40,000 died from this disease (2).  The incidence of breast cancer has been found to increase 
exponentially with age, until the onset of menopause (3). 
Development of this disease usually begins in the cells of either the lobules (milk-
producing glands), the ducts (tubes that branch from the lobules through which milk flows 
from the lobule to the nipple, or in rare cases, the stroma or connective tissue, of the breast 
(Figure 1.1).  As with many other cancers, breast cancer develops along a continuum of 
stages: from hyperplasia to atypical ductal hyperplasia (4), precancerous lesions characterized 
by abnormal cell layers in the ducts or lobules, to ductal carcinoma in situ (DCIS), non-
invasive lesions containing abnormal cells, to malignant or invasive breast cancer (IBC), 
where cancerous cells invade the surrounding tissue and spread to the lymph nodes or other 
organs (5).  In addition to the different stages, grades, and types of breast cancer, the 
expression levels of estrogen receptor (ER), progesterone receptor (PR), ErbB2 (HER2), are 
also used to assess treatment options for breast cancer patients. 
Estrogen is an essential hormonal regulator in normal female development and 
physiology, including that of the mammary glands.  In pre-menopausal women, estrogen is 
synthesized primarily in the ovaries, whereas in post-menopausal women, the main source of 
estrogen the adipose tissue.  The effects of estrogen on the cellular processes of proliferation 











(7) and ERβ (8), nuclear hormone receptors encoded by separate genes located on different 
chromosomes.  Both receptors share similar homology in their ligand- and DNA-binding 
domains, as well as the ability to function as transcription factors to control the expression 
of ER target genes (9). However, ERα is primarily expressed in the breast and female 
reproductive organs, whereas ERβ is more widely distributed (10).  Due to its predominant 
expression in the breast, ERα is responsible for most of the estrogenic effects on both 
normal and oncogenic breast tissue through either genomic (Figure 1.3a) or non-genomic 
mechanisms (Figure 1.3b).  
Genomic (classical) ERα signaling occurs upon estrogen binding of ERα, causing a 
conformational change in the receptor, ERα phosphorylation, dimerization, and activation, 
where ligand-bound-ERα binds cofactors, such as coactivators AF1 and AF2 (Figure 1.4).  
This ligand-receptor-cofactor complex then undergoes a conformational change and 
collectively binds estrogen response elements (EREs), specific DNA sequences in the 
promoter regions of target genes, to control ER target gene transcription (11).  (Non- 
classical) ERα signaling may also occur via ligand-bound-ERα formation of a complex with 
cofactors Fos and Jun to bind AP-1 binding sites, activating target genes lacking EREs.  
Genomic ERα activation may occur not only by ligand-receptor interaction, but also via 
growth factor membrane receptor signaling such as through the IGF1 or EGFR families, by 
direct phosphorylation of ERα or its cofactors (12).  Non-genomic ERα activation occurs 
outside the nucleus where cytoplasmic ERα interacts with various intracellular signaling 
pathways such as the cyclic AMP/cAMP-responsive-element-binding protein (CREB), 
mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3-kinase (PI3K) 










Figure 1.2. Domain structures of ERα and ERβ.  Both human ERα and ERβ share 
structural domains (A-F).  From a functional perspective, ERs are divided into three parts: 
the amino-terminal or A/B domain, the DNA-binding or C domain, and the ligand-binding 














Figure 1.3. Simplified model of the genomic and non-genomic modes of estrogen 
action.  A. The classical mode of action of ERs involves ligand binding to the cytoplasmic 
receptor, translocation to the nucleus and binding to estrogen response elements (EREs) in 
gene promoters, resulting in the induction of gene transcription.  Once bound to the ERE, 
further factors (not shown), such as AF1 and AF2, as well as co-activators, are involved in 
the induction of gene transcription.  Last, transcription factors and RNA polymerase 
complement the transcription machinery.  B. In addition to this genomic mode of action, 
ERs might interact directly with various intracellular signalling pathways, including the cyclic 
AMP/cAMP-responsive-element-binding protein (CREB), mitogen-activated protein kinase 
(MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways, thereby indirectly affecting the 
transcription of several other target genes (13). 
  
 6 
 At least 70% of breast cancers are identified as ER-positive in that their growth is 
dependent on estrogen.  Due to this fact, interference with estrogen action has been an 
essential means of breast cancer treatment as early as 1896, where Beatson reported that 
surgical removal of the ovaries from advanced breast cancer patients led to tumor regression 
and improved diagnosis (14).  Although oophorectomy and eventually ovarian irradiation 
became standard for pre-menopausal patients into the 1960s, only one-third of patients 
responded to such treatments (15).  In the 1970s, development of the estrogen-ER binding 
theory with regard to estrogen action in breast cancer led to the synthesis of competitive 
inhibitors against estrogen binding to ER and the development of the most established and 
widely used selective estrogen receptor modulator (SERM), tamoxifen (16).  After tamoxifen, 
other drugs were developed as alternative endocrine therapies, such as fulvestrant, whose 
mode of action is to bind, block, and lead to ubiquitination and proteosomal degradation of 
ER, inhibiting ER signaling (17), as well as aromatase inhibitors (18), which inhibit estrogen 
synthesis, and whose third-generation non-steroidal AIs letrozole and anastrozole and 
steroidal AI exemestane (19). 
 TAM is a non-steroidal triphenylene derivative and works as a competitive inhibitor 
against estrogen to bind ER.  Upon TAM binding to ER, the receptor dimerizes and binds 
DNA, where, in contrast to estrogen, TAM blocks the transcriptional activating function of 
AF2, as AF2 activation is hormone-dependent, and therefore inhibits activation of AF2 ER-
target genes, impeding breast cancer cell survival and proliferation.  The coactivator AF1 
does not require ligand-binding and thus, retains its activity upon TAM binding, transcribing 
ER target genes that require AF1 action (Figure 1.4). 
In spite of the partial activation of AF1 ER target genes, TAM has been highly 





Figure 1.4. Mechanism of action of estradiol/estrogen (E) compared to tamoxifen 
(T) at the level of transcriptional regulation.  E binds to ER, leading to dimerization, 
conformational change and binding to estrogen response elements.  T competes with E for 





positive breast cancer, almost halving the rate of disease recurrence and reducing the annual 
breast cancer death rate by one-third. Unfortunately, 30-40% of breast cancer patients 
treated with TAM over 5 years eventually relapse within 15 years with distant metastasis, 
most succumbing to their disease (21).  Median overall survival in these patients, even with 
further treatment, is around 30 to 45 months (22). 
1.2 – Mechanisms of tamoxifen resistance (TAMR) 
Extensive studies have identified multiple mechanisms by which breast cancers 
exhibit tamoxifen resistance (TAMR), classified into two categories: intrinsic (de novo) or 
acquired.  Intrinsic TAMR breast cancers are predisposed to be unresponsive to TAM due to 
mutations in the ER ligand binding domain which stabilize ER, rendering it constitutively 
active (23, 24), the lack of ERα expression also via mutation, in this case, rendering the 
tumors functionally ER-negative, inactivation via methylation, truncated ER isoforms, as 
well as post-translational modifications (25).  Another mechanism of intrinsic TAMR 
includes expression of the inactive alleles of the drug-metabolizing enzyme cytochrome P450 
2D6, which fail to convert TAM to its active metabolite endoxifen, rendering tumors less 
responsive to TAM (26). 
Acquired TAMR in breast cancer is characterized by initial response to TAM, which, 
over time, results in eventual relapse and progression.  TAMR occurs through multiple 
mechanisms, including modulation of the ER pathway, such as through increased activity of 
the AP1 and NFB co-activating transcription factors, deregulation of compensatory cellular 
signaling pathways, such as through the MAPK and PI3K/Akt pathways, as well as the 
disruption of cell cycle and apoptosis processes (25).  Although many molecular events that 
confer TAMR are known, a unifying theme is still unknown. 
 
 9 
1.3 – HOX genes 
 The HOX family of homeobox genes is a group of transcription factors essential for 
normal embryonic development, morphogenesis, and cell differentiation highly conserved 
across species. HOX genes collectively contain a common 120-base pair homeobox DNA 
sequence element encoding the 61-amino acid peptide called the homeodomain, which binds 
the consensus core DNA sequence 5’-TAAT-3’ (27).  HOX genes were first described in the 
fruit fly Drosophila melanogaster as the genes responsible for proper spatial body 
development (28).  A series of duplication events throughout evolution is thought to have 
given rise to homologs of these genes throughout vertebrates, and eventually to the 39 HOX 
genes found in humans.  Human HOX genes are organized into 4 paralogous clusters named 
A, B, C, and D, where each cluster is localized on a different chromosome and may contain 
from 9 to 13 genes numbered 1-13 according to their 3’ to 5’ order of alignment (29).  The 
HOX gene family members function as transcription factors, acting as monomers or 
heterodimers with the three-amino-acid-loop extension or TALE cofactors; however, due to 
their evolutionary duplication and clustering across species, HOX genes in higher, more 
complex animals exhibit functional redundancy, notably across the paralogs. 
The HOX genes follow a specific spatio-temporal colinearity or pattern of 
expression that reflects their genomic order in their respective clusters, where the 3’ to 5’ 
organization of the HOX genes on the chromosome corresponds to the order and timing of 
their expression along the anterior-posterior axis of the developing animal (Figure 1.5).  
HOX genes also exhibit posterior prevalence, where HOX genes located more 5’ within the 








Figure 1.5. Genomic organization and colinear expression patterns of Drosophila 



















HOX genes function as transcription factors that regulate essential processes in the 
body, such as cell differentiation and proliferation in embryonic development, as well as cell 
motility and apoptosis, important functions in adult tissue (29).  HOX gene expression is 
frequently deregulated in numerous types of cancer (Figure 1.6).  In breast cancer, the loss of 
HOXA5 and HOXA10 expression has been associated with high-grade breast tumors, 
leading to decreased apoptosis and p53 expression (31, 32), whereas overexpression of 
HOXB7 and HOXB13 has been shown to play respective roles in aggressive disease and 
TAMR (33, 34). 
1.4 – HOXB13 and TAMR 
 HOXB13 was the last human HOX gene to be identified, located about 70 kilobases 
upstream of the HOXB cluster on chromosome 17.  HOXB13 is normally expressed in the 
posterior body axis, including the spinal cord, urogenital tract, colon, and prostate, 
functioning as a regulator of terminal cellular differentiation (35).  Loss-of-function 
mutations in HOXB13 in mice result in the structural overgrowth of major tissues derived 
from the tail-bud, as well as decreased apoptosis in the secondary neural tube during 
development (36). 
  Aberrant expression of HOXB13 is associated with a number of different cancers.  
With regard to prostate cancer, where HOXB13 is expressed in the normal prostate and is 
vital to the normal development of this tissue, downregulation of HOXB13 has been shown 
to cause loss of differentiation as well as the transactivation of AR and cell proliferation in 
prostate cancer (37, 38).  Also, the recurrent HOXB13 G84E mutation in prostate cancer 
has been found to be a prostate cancer susceptibility allele, associated with early-onset and 
hereditary disease (39).  Downregulation of HOXB13 has also been shown to induce 
tumorigenesis in colon cancer (40).  In tissues where its expression is normally absent, 
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upregulation of HOXB13 has been shown to cause invasion potential in endometrial cancer 
(41) and to cause tumorigenesis and abrogation of the antagonistic effects of TAM in 
ovarian cancer (42).  
  Seminal studies regarding aberrant HOXB13 expression in breast cancer highlighted 
the ratio of high HOXB13 to low interleukin-17- receptor (IL17BR) mRNA expression as 
a marker of predictive outcome via gene expression profile analysis of hormone-positive 
primary breast cancer in patients treated with adjuvant TAM mono-therapy (43).  A high 
ratio of HOXB13/IL17BR (H:I) was associated with increased relapse, tumor aggressiveness, 
TAM treatment failure, and death in breast cancer patients (43, 44).  Breast cancers in 
TAMR patients were also found to exhibit high HOXB13 expression, where HOXB13 
overexpression was shown to be repressed by estrogen and this repression was inhibited in 
the presence of TAM.  The Breast Cancer Index or BCI was developed as a combination of 
the H:I ratio with the molecular grade index of MGI of 5 other TAMR biomarkers (45), 
shown to predict long-term recurrence risk after 5 years of not only TAM but also AI 
treatment, making this biomarker relevant to the clinical management of breast cancer (46). 
 For nearly a decade, HOXB13 was known as an important biomarker of TAMR, but 
its role in the disease was unclear.  Our recent studies provided some insight into the 
mechanism whereby HOXB13 mediates TAMR and metastasis.  We showed that TAMR 
and metastasis could be mediated via induction of IL6 expression and subsequent activation 
of its signaling pathway (33) and have now performed further work into targeting aspects of 
the IL6 pathway as a means of treatment.  This work shows that targeting the IL6 receptor 
(IL6R) using tocilizumab, an anti-IL6R antibody, is an effective treatment against the growth 
of HOXB13-overexpressing, TAMR cell line models.  Thus, tocilizumab may prove to be a 
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novel and promising drug candidate for the therapy of HOXB13-overexpressing TAMR 
breast cancer.  
 15 
CHAPTER 2 
Materials and Methods 
Human tissue specimens.  Normal breast epithelial preparations (organoids), primary 
breast tumors, and distant metastases were accessed with approval from the Johns Hopkins 
University Institutional Review Board, and RNA extracted as previously described (47).   
Briefly, tissues from reduction mammoplasty performed at Johns Hopkins Hospital were 
mechanically macerated, and then digested overnight with hyaluronic acid and collagenase.  
The terminal ductal units were placed into suspension, and then isolated by serial filtration.  
Samples were treated with TRIzol and RNA extracted.  Fresh frozen primary breast tumors 
were obtained from the Department of Surgical Pathology tumor bank; specimens were 
from patients 45-55 years of age with localized disease, with positive estrogen receptor 
expression by immunohistochemistry as performed during routine staging at diagnosis, for 
uniformity of samples.  Metastatic breast carcinoma samples were obtained from the Rapid 
Autopsy Program at Johns Hopkins Hospital.  All specimens were fast frozen at autopsy and 
stored at -80°C.  Twenty 20-micron-thick sections were obtained from tumor metastases and 
macerated with the BioMasher sample preparation device (Cartagen), with 350 μL of lysis 
buffer from the Qiagen RNEasy Mini Extraction kit.  RNA extraction was completed with 
the flow-through from the BioMasher, as per the manufacturer protocol.  10 micron-thick 
H&E-stained tissue sections were made from all tumor samples and were confirmed to have 
at least 70% non-necrotic neoplastic epithelial cellularity before RNA extraction. 
 
Cell culture, plasmids, and cell line constructs.  The breast cell lines MCF7 and BT474 
were provided by NCI (IBC-45 panel) through the American Type Culture Collection 
(ATCC) and the human mammary fibroblast cell line 82-6 was provided by Judith Campisi 
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(48).  MCF7 cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% FBS (Gemini Bio-Products), BT474 cells were grown in RPMI 
media with 10% FBS, and 82-6 cells were grown in DMEM F-12 50/50 with 10% FBS.  
Plasmids containing the full length cDNA of human HOXB13 in the pLPCX retroviral 
vector (pHOXB13), the empty pLPCX vector (Clontech), 2 short hairpin RNA (shRNA) 
lentiviral constructs targeting HOXB13 mRNA (shHOXB13) and scrambled shRNA 
construct (PLKO.1/Thermo Scientific) were used to generate viral supernatant for 
overexpression or knockdown of HOXB13 in cell lines (33). 
 
Plasmid Constructs, Viral Packaging, and Cell infection.  A plasmid containing the full 
length cDNA of human HOXB13 in the pDNR-LIB vector (catalog number MHS1011-
62759), a set of short-hairpin RNA microRNA (shRNAmir) lentiviral constructs targeted 
against the HOXB13 mRNA (RHS4533), and a non-silencing lentiviral shRNAmir 
(RHS4346) were purchased from Open Biosystems.  The HOXB13-pDNR-LIB vector was 
digested with the restriction endonuclease Sfi1 and the HOXB13 cDNA ligated into the 
retroviral vector pLPCX (Clontech) with T4 DNA ligase.  The plasmid was transformed into 
Turbocells competent E. coli (Genlantis) per manufacturer protocol, which was then 
selected on LB agar supplemented with ampicillin (100 μg/mL).  The resultant plasmid and 
the shRNAmir plasmids were amplified in LB broth with ampicillin and purified with the 
QuantumPrep Plasmid Midiprep kit (Bio-Rad).  Sequences were confirmed with the Applied 
Biosystems 3730xl DNA Analyzer.  The plasmids were then co-transfected with pCL-
Ampho packaging vector (pLPCX) or psPAX2 and pMD2.G packaging vectors (lentiviral 
plasmids) into HEK-293T cells with Lipofectamine 2000 (Life Technologies), and viral 
supernatant collected at 36 and 72 hours.  MCF7 and T47D cells were treated with DEAE-
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dextran-containing media, then the HOXB13-pLPCX or pLPCX-vector control viral 
supernatant for 24 hours.  Infected cells were re-plated and treated with media containing 
puromycin, 0.2 μg/mL, for 2 weeks.  Clones were selected and HOXB13 expression 
evaluated.  The BT474 cell line was treated with DEAE-dextran containing media, then viral 
supernatant from either the non-silencing shRNAmir (Scramble or Scr) or constructs against 
HOXB13 for 24 hours.  The cell lines were re-plated and treated with media containing 
puromycin, 0.1 μg/mL for 2 weeks.  The propagated colonies were then re-infected with 
either shScramble, or HOXB13-targeting shRNAmir clones TRCN0000020844 
(shHOXB13-1) or TRCN0000020845 (shHOXB13-2), and infected cells reselected with 
puromycin 0.2 μg/mL.  The resultant clones (BT474-Scr, BT474 B13 KD-1, and BT474 B13 
KD-2) were then tested to confirm loss of HOXB13 expression.  All cell lines were 
maintained in media supplemented with puromycin 0.2 μg/mL.  Experiments were 
performed in media without puromycin. 
 
Promoter-lucifrase reporter assay.  MCF7 cells were transiently transfected with 
Lipofectamine 2000/DNA complexes (Life Technologies) of pGL2-HOXB13, promoter-
luciferase construct (pGL2; Promega), and -galactosidase (-gal) plasmid, and incubated for 
24 hours.  Luciferase and -gal activity were measured per protocol (Promega).  Assays were 
conducted in triplicate in a single experiment, and then as 3 independent experiments. 
 
Chromatin Immunoprecipitation (ChIP). ChIP was performed with the EZChip kit 
(Millipore) according to protocol.  2.5 x 106 cells were seeded into 15 cm plates and grown to 
90% confluency.  Protein and DNA were crosslinked with 1% formaldehyde in water and 
collected.  Cells were sonicated with a Branson 450 ultrasonicator (4 cycles of 30 seconds 
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each, 30% Duty cycle, output 4) on ice.  The resulting lysate was either stored as input DNA 
or immunoprecipated with anti-HOXB13 antibody (F-9, Santa Cruz), normal mouse IgG, or 
anti-RNA Polymerase II (Millipore) overnight at 4°C after pre-clearing, then complexes 
collected with ChIP-grade Protein G Agarose.  The DNA crosslinking was reversed and 
DNA purified by spin column.  2 μL of the eluted DNA was then used for PCR, using 
primers designed to noted regions of the IL6 promoter, extending 2000 bp upstream of the 
transcription start site.  PCR was performed using BlueTaq polymerase (Denville Scientific), 
using the provided buffer, per manufacturer protocol.  Half of each reaction was run on 1% 
agarose/LB gel.  Amplification of DNA in the input and anti-HOXB13 fractions and lack of 
amplification in the normal IgG fraction were indicative of specific binding of the probed 
DNA region by the HOXB13 antibody. 
 
Microarray analysis. Gene expression microarray analysis was performed on BT474-Scr 
and two clones of BT474-B13 KD cells. The data was analyzed (by Sean Soonweng Cho) 
using the R statistical environment using packages from Bioconductor and custom functions 
when necessary.  The data was RMA normalized and log2 converted for further analysis.  
Unsupervised hierarchical clustering was performed on 500 most differentially expressed 
genes across all three samples.  Unsurprisingly, the BT474 B13 KD knockdown cell lines 
formed a tight cluster compared to the BT474-Scr control.  To identify genes that are 
differentially expressed between knockdown and control cells, we compared the log2 
expression of both conditions and genes with a log2 fold change of larger than 1 is 
considered differentially expressed. 
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Cell line RNA extraction and quantitative real-time PCR (qRT-PCR) validation of 
gene expression.  Cells were grown in 6-well plates and harvested at equal density (approx. 
80% confluence) with TRIzol (Life Technologies).  RNA was then extracted and purified per 
manufacturer protocol.  A total of 2 g of RNA from cell lines was reverse-transcribed using 
MMLV-RT (Promega).  Primers were designed using Primer3 (49) to span an intron.  qRT-
PCR was then performed using the Maxima SYBR Green/ROX Master Mix (Fermentas) per 
manufacturer protocol.  Gene expression was analyzed by the Ct method, with GAPDH 
expression used for normalization. 
 
Western blot analysis.  Cells were grown in 6-well plates and after 24 hours, medium was 
changed to either complete medium with phenol red supplemented with 10% heat-
inactivated fetal bovine serum, or phenol red-free medium supplemented with 5% charcoal-
stripped FBS and treated with the drug specified.  At the indicated time, cells were washed 
with PBS and lysed with RIPA buffer for 1 hour and then centrifuged for 30 minutes at 4C.  
Total protein concentration was measured using the BCA Protein Assay according to the 
manufacturer’s protocol.  Equal amounts of extracted lysate were vertically electrophoresed 
on a 4-12% Bis-Tris NuPage Novex Gel in MOPS SDS running buffer (Life Technologies), 
then transferred to a Hybond C Extra membrane (GE Healthcare).  Membranes were 
stained with Ponceau stain to confirm protein transfer, then blocked with 5% nonfat dry 
milk in PBS with 0.2% Tween-20 (PBST) for one hour at room temperature.  Membranes 
were probed with primary antibody in 5% Bovine Serum Albumin (BSA)/PBST at 4C 
overnight, rinsed with PBST, then probed with secondary antibody (GE Healthcare) at 
1:4500 dilution in 5% milk/PBST for 1 hour.  After rinsing with PBST, membranes were 
treated with ECL Plus Detection Reagent (GE Healthcare) for 1 minute, and exposed to 
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HYblot CL autoradiography film to determine protein expression.  Antibody against 
HOXB13 was purchased from Santa Cruz; antibodies against beta-catenin, STAT3, Akt, and 
P70S6K were purchased from Cell Signaling; GAPDH antibody was purchased from 
Millipore. 
 
MTT assay.  2.5x103 cells/well were plated in 96-well plates in triplicate and treated with 
the indicated drug concentrations, alone, or in combination.  After 48 hours, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Quality Biologicals) solution 
(5 μg/mL) was added, cells incubated for 3 hours, dissolved in 1:1 DMSO:EtOH, and 
absorbance at 560 nm was measured, with background at 670 nm subtracted.  Values are 
expressed as percent survival of the vehicle-treated control (given as 100%). 
 
Migration assays.  Migration assays were performed in BD BiocoatTM Control (24-well 
format) Invasion Chambers per manufacturer protocol.  750 L of chemoattractant was 
used.  8x103 82-6 Immortal Human Mammary Fibroblast cells were placed in the chamber in 
500 μL serum-free media.  Cells were incubated at 37C for 24 hours, and then membranes 
scrubbed, fixed with 15% formalin, and stained with 1.25% crystal violet.  Slides were made 
of the membranes and migrating cells counted.  Cell-conditioned media were tested in 
triplicate. 
 
Tumor xenograft studies.  6-to-8-week-old female NSG mice were used and the study 
approved by the Johns Hopkins Animal Use Committee.  Cells were grown to 90% 
confluence, trypsinized, re-suspended in PBS, and mixed 1:1 with Matrigel (BD Biosciences).  
On day 0, 3x106 cells in total volume 50 μL of MCF7 B13-2 cells were injected 
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subcutaneously (s.c.) into both flanks of each mouse.  Upon palpable tumor, 5 mice with 
subcutaneous tumors were treated with (a) NVP-BEZ235 (50), 25 mg/kg administered 
orally (p.o.) dissolved in 10% NMP-90% PEG, freshly formulated, dose administrated 
within 30 minutes, (b) Tocilizumab, 100 ug intraperitoneally (i.p.) or (c) NVP-BEZ235 and 
Tocilizumab, or (d) no treatment.  In a second experiment, 6-to-8-week-old female NSG 
mice were used and the study once again approved by the Johns Hopkins Animal Use 
Committee.  Cells were grown to 90% confluence, trypsinized, resuspended in PBS, and 
mixed 1:1 with Matrigel (BD Biosciences).  On day 0, 3x106 cells in total volume 50 μL of 
MCF7-Vector, MCF7 B13-2, BT474 B13 KD-2, or BT474-SCR cells were injected s.c. into 
both flanks of each mouse.  Upon reaching 100 mm3 tumor size, 5-6 mice each with two 
subcutaneous tumors (10-12 tumors) were treated as above with either (e) Tocilizumab, (f) 
Tamoxifen (51) 500 μg administered s.c., suspended in peanut oil, freshly formulated, dose 
administrated within 30 minutes, or (g) Tocilizumab and Tamoxifen, or (h) no additional 
treatment.  Tumor growth was measured about every 3 days.  Mice were euthanized after 6 
weeks of treatment and tumors harvested, sectioned and flash-frozen, or formalin-fixed and 
paraffin-embedded and H&E slides made.  Tumor volume was estimated by the calculation 
V = (length x width x height x 0.5236) mm3. 
 
Statistical analyses.  Results were expressed as mean  standard error of the mean (52) of 
at least 3 independent experiments.  All statistical tests were two sided, and differences were 






HOXB13 mediates tamoxifen resistance and invasiveness 
in human breast cancer by inducing IL6 expression  
3.1 – HOXB13 is overexpressed in primary ER-positive breast cancers and distant 
metastases 
In order to verify HOXB13 overexpression in breast cancer, we interrogated ER-
positive breast cancer samples from breast cancer survivors, non-survivors, and metastases 
from multiple tissues for HOXB13 expression by qPCR.  Compared to normal organoids, 
each group of tumors had significantly higher expression of HOXB13.  Tumors from non-
survivors and metastases showed even greater overexpression of HOXB13 compared to 
those from survivors (Figure 3.1), thus confirming HOXB13 overexpression in ER-positive 
breast cancers and distant metastases. 
3.2 – HOXB13 overexpression promotes TAMR 
Based on the above data demonstrating HOXB13 overexpression in clinical samples 
of ER-positive breast cancer, which was higher in non-survivors and metastases, we 
hypothesized that HOXB13 plays an integral role in tumor progression in patients with ER-
positive breast cancer.  In order to study the mechanism by which HOXB13 mediates tumor 
progression to TAMR and distant metastasis, we created stable clonal cell line models of 
HOXB13 expression; two stable clonal cell lines of HOXB13-overexpressing were made in 
MCF7 (MCF-7-B13-1 and -2), and reciprocally, stable clonal cell lines were also created 
where HOXB13 was knocked down with shRNA in the BT474 cell line (BT474-shB13-1 










Figure 3.1. HOXB13 is overexpressed in primary ER-positive breast cancers and 
distant metastases. qPCR validation of HOXB13 expression in normal breast organoids 
(Org), ER-positive primary breast tumors from long-term survivors or non-survivors of 





Figure 3.2.  HOXB13 overexpression promotes TAMR. A, qPCR analysis of HOXB13 
expression in MCF7 and BT474 HOXB13-expressing cell line panels compared with vector 
control; cell viability after treatment with 1, 2, or 5 mmol/L 4-OH TAM. B, tumor growth 
of MCF7-vector (black) and MCF7- HOXB13 cell subcutaneous xenografts in athymic mice 
with E2 supplementation, then treated with subcutaneous TAM implant (arrow; *, P<0.01); 
tumor growth of BT474-scrambled shRNA (closed square) and BT474- HOXB13 shRNA 
(open square) cell subcutaneously xenografts in athymic mice with E2 supplementation, then 










To determine if HOXB13 overexpression correlated with TAMR, we treated MCF-
7-HOXB13 clones with increasing concentrations (1 to 5 μM) of 4-hydroxytamoxifen (4-
OH TAM, the active metabolite of TAM) for 48 hours and tested for cell viability.  The 
HOXB13-overexpressing cells showed higher cell survival to TAM treatment at higher 
concentrations as opposed to vector control in MCF7 and in BT474, the HOXB13-
expressing BT474-Scr cell line also showed higher cell survival to TAM treatment, whereas 
HOXB13 knockdown rendered these BT474 clones sensitive to TAM, decreasing their 
survival (Figure 3.2a).  Growth phenotypes of these cells were also tested in vivo.  TAM 
treatment of MCF7 vector control xenografts resulted in regression of the tumors, whereas 
TAM treatment did not have a significant effect on the growth of MCF7 HOXB13-
overexpressing xenografts which continued to grow despite TAM (Figure 3.2b).  HOXB13-
expressing BT474-Scr tumors also continued to grow upon TAM treatment, whereas the 
BT474 HOXB13 knockdown tumors regressed.  Thus, MCF-7 respond to tamoxifen, while 
high HOXB13 expressing MCF-7-HOXB13 cells do not. Conversely, BT47scr cells are high 
HOXB13 expressors, and are resistant to the effects of TAM, while the HOXB143-KD cells 
are susceptible to tamoxifen.  Collectively, these data reflect the TAMR phenotype is 
associated with HOXB13 overexpression as shown in vitro and in vivo. 
3.3 – HOXB13 promotes stromal recruitment via IL6 upregulation 
Upon examining the histology of the MCF7 xenografts, we observed a more 
prominent stromal component (Figure 3.3a) in MCF7-HOXB13-overexpressing tumors 
compared to vector control, which showed growth as tight, uniformly spaced, carcinoma 
cells with little stromal presence.  Because stromal recruitment is known to participate in 
breast cancer aggression (18, 53, 54), we hypothesized that mechanisms that drive HOXB13-











Figure 3.3.  HOXB13 promotes stromal recruitment via IL6 upregulation.  A, 
Hematoxylin and eosin-stained sections of MCF7 xenografts.  MCF7 vector tumors on the 
left grow as uniform sheets of cancer cells, with little stromal component.  In contrast, 
MCF7 HOXB13 tumors on the right have significantly more stromal infiltration.  B, qPCR 
analysis of IL6 expression in MCF7 HOXB13 on the left and BT474 HOXB13-KD on the 
right compared with the control cells. C, Cell invasion/chemotaxis analysis using MCF7 
HOXB13-conditioned media as the chemoattractant for untreated NIH3T3 fibroblasts or 














stroma-tumor crosstalk.  Thus, we tested a panel of cytokines involved in stromal 
recruitment and cell invasion (not shown) by qPCR to test if their mRNA expression 
correlated with that of HOXB13.  We found that interleukin-6 (IL6) is consistently 
expressed in high HOXB13-expressing MCF-7 but not in the MCF-7 vector transfected cell 
lines (Figure 3.3b). 
In order to evaluate the ability of HOXB13-expressing breast cancer cells to recruit 
fibroblasts and to define the role of secreted-IL6 as a cytokine in this function, we 
performed fibroblast migration assays with both NIH3T3 murine fibroblasts and human 
fibroblasts.  In a Boyden chamber assay, we tested fibroblast migration from inside the 
chamber to the outer membrane towards conditioned media collected from MCF-7 vector 
control or MCF7 HOXB13-overexpressing cell lines placed in the lower chamber (Figure 
3.3c).  We observed a significant increase in the number of migrating fibroblasts toward 
conditioned media from MCF7 HOXB13-overexpressing cells as opposed to the number 
migrating towards the medium from the MCF-7 vector control.  
To determine if the migration is mediated largely through the presence of IL6 in the 
HOXB13-overxpressing tumor cell conditioned medium, we performed the following test.  
Upon pre-treatment of the human fibroblasts with a neutralizing anti-IL6R antibody, the 
increase in the number of migrating cells observed was abrogated, suggesting that by 
blocking the IL6 receptor on the migrating cells, their attraction towards the cytokine was 
significantly reduced.  Thus, IL6 was the major stromal chemoattractant presented in the 
conditioned medium, which was secreted by the HOXB13 overexpressing carcinoma cells. 
3.4 – IL6 is a direct transcriptional target of HOXB13 
Because HOXB13 functions a transcription factor, we wanted to investigate the 






Figure 3.4.  IL6 is a direct transcriptional target of HOXB13.  A, IL6 promoter-
luciferase construct maps on the left and luciferase activity of each construct, co-transfected 
with vector in red or pHOXB13 in blue, identifying a region 248 bp upstream of the TSS, 
including 2 HOX binding sequences, as critical to HOXB13-directed enhancement (*, 
P<0.01).  B, Diagram of regions in the IL6 promoter with HOXB13 binding sites (double 
arrow).  ChIP on MCF7 HOXB13 cells with either anti-HOXB13 antibody or control IgG 
shows Site 3 is enriched with HOXB13 expression (bottom). C, qPCR analysis of the 3 
putative HOXB13 binding sites in the IL6 promoter after HOXB13 ChIP assay.  D, qPCR 
analysis of HOXB13 binding Site 3 after PBX1, NCOR, or MEIS1 ChIP assay (*, P<0.01). 
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could occur via direct binding of HOXB13 to the IL6 promoter, and/or protein-protein 
interaction and binding of HOX co-factors, and the resulting activation of IL6 transcription.  
To evaluate if HOXB13, as a transcription factor, was directly driving IL6 transcription, we 
performed luciferase activity assays.  Constructs containing 1.7 kb of the IL6 promoter and 
its deletions were linked to the luciferase reporter gene, and were transiently transfected into 
MCF7 cells along with HOXB13 expression plasmids.  No significant activation of the 
luciferase gene was observed with the -1787 or -1228 bp or the -532 bp promoter fragments.  
However, four-fold activation was observed with the -439 bp construct, suggesting that 
negative transcriptional elements may reside in the longer constructs (Figure 3.4a).  Deletion 
of the promoter sequence up to -248 retained the ability of HOXB13 to activate the 
luciferase construct.  To test whether this activation is HOXB13-mediated, we prepared 
constructs that deleted each of the putative binding sites for HOXB13. Deletion of any one 
of three putative HOXB13 binding sites in the -248 bp construct within the IL6 promoter 
abrogated luciferase activity, indicating the requirement for all three binding sites for 
HOXB13 mediated promoter activation as tested by this assay.  
In order to better define which putative site in IL6 is the vital binding site for 
HOXB13, we interrogated the three putative HOX binding sites identified above in the -248 
bp fragment of the IL6 promoter region close to the transcriptional start site by performing 
a ChIP assay.  Control IgG or anti-HOXB13 antibody was used to immunoprecipitate 
HOXB13 complexes crosslinked to the IL6 promoter DNA fragments in MCF7 HOXB13-
overexpressing cells.  We observed that site 3 (-225 to +15 bp of the TSS), but not the other 
two sites, was enriched for HOXB13 binding in MCF7 HOXB13-overexpressing cells as 
shown by PCR products fractionated on an agarose gel (Figure 3.4b).  qPCR analysis of the 
three putative IL6-promoter binding sites also showed enrichment of site 3 specifically in 
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MCF7 HOXB13-overexpressing cells compared to vector control (Figure 3.4c).  To 
investigate possible binding of HOXB13 to HOX co-factors vital for transcriptional 
regulation, we performed ChIP assays on the three different HOX co-factors PBX1, NCOR, 
and MEIS1, and observed enrichment at site 3 for the co-activators PBX1 and MEIS1, but 
not of the co-repressor NCOR (Figure 3.4d).  These findings support the hypothesis that 
HOXB13 binds the IL6 promoter directly and promotes IL6 transcription. 
3.5 – The IL6 pathway is activated in HOXB13-expressing cells 
 IL-6 is known to promote tumorigenesis through multiple mechanisms, such as cell 
proliferation and stromal recruitment (55-57) and causes these effects via phosphorylation of 
the downstream effectors STAT3, PI3K/AKT and mTOR (Figure 3.5a – IL6 pathway 
diagram) of its pathway.  Thus, we decided to interrogate the activation of the IL6 pathway 
in our HOXB13-expressing cell lines by western blot analysis.  Consistent with signaling 
activation as a result of IL6 ligand action on IL6R, we observed that although total-STAT3 
levels did not change, there was increased phosphorylated STAT3 (P-STAT3) at tyrosine 705 
in MCF7 HOXB13-overexpressing cells compared to vector control.  Similar relationships 
were also observed between AKT at serine 473 and in P70S6K and 4EBP1, the downstream 
effectors of mTOR action in the MCF7 HOXB13-overexpressing lines.  BT474-Scr cells 
exhibited higher phosphorylated STAT3, AKT, P70S6K, and 4EBP1, where these levels 
were reduced in the BT474 HOXB13-KD clones, without any significant changes in the 
levels of the total proteins, confirming specific induction of IL6 pathway components in our 
























Figure 3.5b and 3.5c.  IL6 signaling pathway activation in HOXB13-expressing 
breast cancer cells and recruited fibroblasts.  A, Western blot analysis of p-STAT3 
(Y705), p-AKT (S473), p-p70S6K, and p-4EBP1 in MCF7 HOXB13 and BT474 HOXB13-
KD cells compared with control cells.  B, Western blot analysis of p-STAT3 (Y705) and p- 
AKT (S473) in human fibroblasts after treatment with conditioned media from MCF7 
vector or MCF7 HOXB13 cells, with and without treatment of either anti-IL6 on the left or 











Figure 3.6.  Rapamycin can inhibit proliferation of HOXB13-expressing breast 
cancer cells in vitro and in vivo.  A, Cell viability analysis following treatment with 25, 50, 
and 100 ng/mL rapamycin in MCF7 HOXB13 and T47D HOXB13 cells compared with 
vector control cells (*, P<0.005).  B, Growth of MCF7 HOXB13 xenografts implanted in 
athymic mouse mammary fat pad (mfp).  Xenografts grew in the presence of estrogen (E2) 
for 3 weeks; mice were then treated with TAM (square), rapamycin (circle), or rapamycin and 
TAM (triangle) for 3 weeks.  Tumor volume was significantly smaller in rapamycin alone and 









3.6 – Rapamycin can inhibit proliferation of HOXB13-expressing breast cancer cells 
in vitro and in vivo 
 After verifying activation of the IL6 pathway in our HOXB13-expressing cells, we 
looked to interrogate the downstream effector mTOR as a targetable aspect of the IL6 
pathway by inhibiting mTOR activity in our cells with rapamycin.  Upon testing the cell 
viability of MCF7 and T47D HOXB13-overexpressing cell lines upon rapamycin treatment, 
we observed that our HOXB13-overexpressing cells were specifically susceptible to 
rapamycin when compared to vector control (Figure 3.6a).  Given the suppressive effect of 
rapamycin on HOXB13-overexpressing cells in vitro, we further tested sensitivity of our 
HOXB13-overexpressing cells to rapamycin in vivo, also evaluating if there would be an 
additive or synergistic effect of using rapamycin with TAM.  After MCF7 HOXB13-
overexpresing xenografts were grown for 3 weeks, the mice were treated with estrogen alone, 
TAM alone, rapamycin alone, or rapamycin and tamoxifen in combination.  Rapamycin 
alone and in combination with TAM caused marked tumor regression (with no additive nor 
synergistic effect for rapamycin treatment in combination with TAM) and was significantly 
more effective than TAM alone (Figure 3.6b), showing that by targeting the activated mTOR 
pathway in HOXB13-overexpressing cells, we could specifically inhibit their proliferation. 
The observations in this paper regarding HOX13 expression show that HOXB13 is 
overexpressed in ER-positive breast cancer and metastases.  The experiments conducted in 
cell culture and in vivo suggest that HOXB13 overexpression promotes TAMR as well as 
stromal recruitment through IL6 upregulation mediated by the direct binding of HOXB13 to 
the IL6 promoter, resulting in an induction of IL6 transcription.  We also found that in the 
HOXB13-expressing cells themselves, the IL6 pathway is upregulated and that by targeting 
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the downstream effector mTOR with rapamycin, we can inhibit HOXB13-overexpressing 

























Discovery of novel targets associated with HOXB13-expression 
4.1 – Novel targets display correlation between mRNA expression and HOXB13-
expression 
 We used a two-pronged approach to our goal of discovering genes that are altered by 
HOXB13 expression.  The first, using microarray analysis to discover new targets associated 
with HOXB13-expression in our cell line models, and the second, to better define other 
downstream effectors of the IL-6 pathway that may be more accessible, more effective 
targets to inhibit HOXB13-mediated-TAMR.  In order to investigate genes possibly 
regulated by HOXB13-overexpression that may contribute to TAMR, we performed an 
Affymetrix GeneChip PrimeView Human Gene Expression Array on our BT474 cell line 
panel, which consisted of BT474-Scramble (BT474-Scr) control, which exhibits endogenous 
high expression of HOXB13 as well as is inherent tamoxifen resistant, and BT474 HOXB13 
knockdown (KD) clonal cell lines that we ourselves created (Figure 4.1).  The heat map 
generated through microarray analysis shows differential expression between the BT474 
scramble control and HOXB13 knockdown cell lines (Figure 4.2). 
From this analysis we selected the top 5 upregulated and the bottom 5 
downregulated genes from our list of differentially expressed genes (Table 4.1) and validated 
their expression in the BT474 cell line panel by RT-qPCR (Figure 4.3), and observed that 
upregulated genes in the microarray were overexpressed in scramble compared to the 
knockdown-HOXB13 lines and vice-versa with the downregulated genes.  From the list of 










Figure 4.1. Validation of HOXB13-expressing cell line model panels.  Western blot and 
qPCR analysis of HOXB13 expression in CAMA1 and MCF7 HOXB13-overexpressing cell 
line panels compared with vector controls confirm HOXB13-overexpression for both 
mRNA and protein levels; reciprocally, the BT474 HOXB13-KD cell line panel also 










Figure 4.2. Differential expression observed after microarray analysis between BT474 
scramble control and the BT474 HOXB13-KD cell lines.  Unsupervised hierarchical 
clustering resulted in the generation of two separate clusters between the BT474 scramble 









Gene Log2FC Function 
CYP2A6 2.97 
Key enzyme for metabolism of xenobbiotics; E2-
induced; cytochrome P450 family 
BASP1 2.89 Brain acid soluble protein 1 
CST1 2.23 Cystatin-SN 
DKK1 2.07 
Dickkopf-related protein 1, inhibitor of Wnt 
signaling, overxps in breast cancer 
COLEC12 2.06 Collectin sub-family member 12 
MERTK 1.14 RTK, promotes invasion in glioblastoma 
TYRP1 -5.34 
Overexpression assoc. with normal tissue or non-
metatstatic tissue 
XAGE1A -5.69 XAGE subfamily of GAGE proteins 
LGALS1 -6.45 
Galectin-1, implicated in modulating cell-cell and 
cell-matrix interactions 
MAGEA3 -7.78 
Melanoma-associated antigen 3, tumor-specific 
antigen of melanoma and lung cancer 
SERPINA6 -8.25 
Serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 6, major 
transport protein for glucorticoids and progestins 
 
Table 4.1. Top 5 upregulated and bottom 5 downregulated genes based on BT474 


























Figure 4.3. Validation of target gene mRNA expression correlation with HOXB13-
expression.  qRT-PCR analysis of the top 5 upregulated and bottom 5 putative target genes’ 



































































4.2 – Dickkopf-related protein 1 (DKK1) 
Dickkopf-related protein 1 or DKK1 is a key inhibitor of the canonical Wnt/Beta-
catenin (B-cat) signaling pathway and is a direct downstream target of B-cat/TCF/LEF 
transcriptional activation (58).  Because DKK1 overexpression has been observed in a wide  
variety of cancers including breast (59), and because B-cat expression is associated with poor 
prognosis in breast cancer patients (60), this suggested an unknown mechanism for an 
oncogenic role for DKK1. 
We hypothesized that if DKK1 overexpression in HOXB13-overexpressing TAMR 
breast cancer correlated with an upregulation of Wnt signaling, we would observe an 
increase in activated (free) B-cat, binding of activated B-cat to the TCF/LEF cofactor 
complex, and induced upregulation of Wnt target genes.  Therefore, we assessed mRNA 
expression of Wnt ligand and co-receptors, as well as the expression of Wnt target genes in 
our HOXB13-cell lines through qPCR. 
Assessment of DKK1 mRNA expression in our HOXB13-overexpressing cell line 
panels found that its overexpression correlated with HOXB13 overexpression in CAMA1 
HOXB13 overexpressing clones and its downregulation correlated with HOXB13 
knockdown in BT474 cells (Figure 4.4).  HOXB13-overexpression in MCF7 did not 
correlate with DKK1 overexpression. 
Both Wnt ligand Wnt3a and Wnt co-receptor FZD1 mRNA expression was found 
to be downregulated in our BT474 B13-knockdown cell lines and overexpressed in only one 
of our CAMA1 HOXB13-overexpressing clones (Figure 4.5), which would suggest 
upregulation of the Wnt pathway.  In spite of this result, we observed the upregulation of 
only one canonical Wnt target gene, Axin2 (Figure 4.6).  Western blot analysis of activated 











Figure 4.4. DKK1 overexpression correlates with HOXB13-expression in CAMA1 and 
BT474 models.  qRT-PCR analysis of DKK1 mRNA levels in MCF7 and CAMA1 
HOXB13-overexpressing cells, as well as BT474 HOXB13-KD cells compared with control 
cells. (*, P<0.001). 
 
Figure 4.5. Wnt ligand and co-receptor overexpression correlates with HOXB13-
expression.  qRT-PCR analysis of WNT3a and FZD1 mRNA levels in CAMA1 HOXB13-












Figure 4.6. Overexpression of Wnt target gene AXIN2 correlates with HOXB13-
expression; expression of Wnt target gene TWIST1 does not.  qRT-PCR analysis of 
AXIN2 and TWIST mRNA levels in CAMA1 HOXB13-overexpressing cells and BT474 












Figure 4.7. HOXB13 expression does not induce WNT signaling.  Western blot 
analysis of free (activated) B-cat in BT474 HOXB13-KD cells and CAMA1 HOXB13-
overexpressing cells compared with control cells. 
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overexpressing panel, there is little to no activated B-cat.  In the BT474 HOXB13-KD panel, 
we observed levels of activated B-cat in the scrambled DKK1/HOXB13 overexpressing cell 
line, however, only in Knockdown 2 was a decrease in activated B-cat observed (Figure 4.7). 
These results suggested that upregulation of DKK1 in HOXB13-overexpressing cells 
seems to have no effect on canonical Wnt signaling/B-cat activation.  Because DKK1 is a 
direct Wnt target gene, increased Wnt signaling would induce its transcription; deregulation 
of Wnt signaling may be so strong that it may override DKK1 inhibition, therefore, making 
DKK1 overexpression an artifact of aberrant Wnt signaling in HOXB13-mediated TAMR 
breast cancer. 
4.3 – C-mer proto-oncogene tyrosine kinase (MERTK) 
MERTK is also known as the C-mer proto-oncogene tyrosine kinase and is a 
member of the TYRO3/AXL/MER receptor kinase family.  It is a potent mediator of pro-
survival and anti-apoptotic signaling pathways and is an upstream activator of MAPK, 
PI3K/Akt, and Jak/Stat pathways.  Downstream of MERTK, there are additional signaling 
pathways important to cytokine production and enhanced migration/invasion (61).  We 
observed MERTK overexpression in correlation with HOXB13 overexpression in our 
CAMA1 and BT474 cell lines; however, this was not observed in MCF7 (Figure 4.8). 
Studies have shown the microRNA miR-126 to be commonly silenced in breast 
cancer and shown to suppress metastasis through inhibition of its target genes, among which 
is MERTK (62).  This study, highlighting the seemingly important role of MERTK in breast 
cancer metastasis, prompted us to investigate MERTK mRNA expression in our store of 
patient tumor samples; however, in spite of expecting an increase in MERTK expression in a 
panel of patient tumor samples.  However, contrary to the predicted increase in MERTK  
 45 
 
Figure 4.8. MERTK overexpression correlates with HOXB13-expression in CAMA1 
and BT474 models.  qRT-PCR analysis of MERTK mRNA levels in MCF7 and CAMA1 
HOXB13-overexpressing cells, as well as BT474 HOXB13-KD cells compared with control 












Figure 4.9. No trend of MERTK overexpression observed in primary breast cancers 
and distant metastases.  qRT-PCR analysis of MERTK expression in normal breast 









Figure 4.10. Diminutive change in DKK1 and MERTK mRNA expression between 









expression in tumor samples, there was no difference in MERTK levels between normal 
organoids, and both primary and metastatic cancer samples (Figure 4.9).  It is likely that 
activated MERTK forms may be overexpressed in breast cancer; thus, this hypothesis 
remains to be tested. 
4.4 – The Cancer Genome Atlas (TCGA) database analysis for DKK1 and MERTK 
 As a final effort to further probe these potential targets regarding tumor aggression 
and metastasis, we queried the TCGA database for both DKK1 and MERTK, where we did 
not see much change in expression between normal and tumor; also, the sample size was too 
small to feel confident about its overexpression in metastatic samples (Figure 4.10). 
Conclusions 
Based on our mixed observations regarding the role of DKK1 and MERTK in 
HOXB13-mediated TAMR, it is obvious that more detailed analysis is needed to determine 














In vitro targeting of the IL-6 pathway in HOXB13-expressing breast cancer 
5.1 – Fibroblast migration toward HOXB13-expressing cell line conditioned media is 
abrogated upon anti-IL-6R antibody Tocilizumab (TOC) treatment 
In addition to the mTOR component of the IL6 pathway that was the focus of our 
investigation (33), we next investigated other important components of the pathway such as 
the IL6 receptor itself, STAT3, and PI3K/Akt, upstream of mTOR, by interrogating the 
effects of various inhibitors (Table 5.1) against these components on our HOXB13-
expressing cell line panels. 
Tocilizumab (TOC) is a humanized monoclonal anti-IL-6R antibody, kindly donated 
for our studies by Genentech, that is FDA approved and is currently used to treat 
rheumatoid arthritis (63).  After treatment of MCF7 HOXB13-overexpressing and BT474 
HOXB13-KD cells with increasing doses of TOC, we observed a slight decrease in MCF7 
HOXB13-overexpressing cell viability compared to vector control.  However, we did not see 
much change, if at all, in the cell viability of BT474-Scr cells compared to BT474 HOXB13-
KD clones upon TOC treatment (Figure 5.1).  This lack of cytotoxic effects of TOC on the 
tumor cells could likely be attributed to their effect on the stroma rather than the tumor cells 
themselves.  Indeed, the first hint of collaboration of the fibroblasts in HOXB13-directed 
tumorigenesis was obtained from our observation that HOXB13 overexpressing tumors had 
a marked stromal component and a desmoplastic response typical of aggressive tumors. 
As a first step, we investigated the effect of TOC on fibroblast migration in Boyden 
chamber assays.  With the exposure of human mammary fibroblast in Boyden chambers to 




















Table 5.1. Panel of IL6 pathway inhibitors tested against HOXB13-expressing cell 
line panels. Rows in bold indicate drugs further pursued in our studies; *TOC did not 
specifically inhibit HOXB13-specific cell viability but did inhibit HOXB13-specific 











Tocilizumab IL6R None* 
Niclosamide STAT3 None 
AS-605240 PI3K None 
BEZ235 PI3K Strong 
GDC-0941 PI3K None 
GSK1059615 PI3K Slight 
IC-87114 PI3K Slight 
LY294002 PI3K Strong 
PI-103 PI3K Strong 
PIK-90 PI3K Slight 
TG100-115 PI3K Slight 
TGX-221 PI3K  None 
XL147 PI3K  None 
ZSTK474 PI3K Slight 
































Figure 5.1. TOC does not significantly inhibit viability of HOXB13-overexpressing 
cells in culture. MTT cell viability after treatment with increasing doses of TOC in MCF7 
HOXB13-overexpressing cells compared with MCF7 vector control and BT474-Scr cells 


























































Figure 5.2. TOC inhibits fibroblast migration toward HOXB13-expressing 
conditioned media.  Cell invasion/chemotaxis analysis using conditioned media from 
MCF7 vector control, MCF7 HOXB13-overexpressed, BT474-Scr, or BT474 HOXB13-KD 
cells as the chemoattractant for primary human fibroblasts untreated or pre-treated with IgG 








































cells, BT474-Scr, or BT474 HOXB13-KD cells, we observed that, as in our previous studies 
that there was a marked increase in the number of migrating fibroblasts toward MCF7 
HOXB13-overexpressing or BT474-Scr conditioned media as opposed to MCF7 vector 
control or BT474 HOXB13-KD conditioned media and that this increase in migration was 
abrogated upon TOC pre-treatment and thereby blocking of the IL6 receptors of the 
fibroblasts (Figure 5.2). 
5.2 – Niclosamide, inhibitor of STAT3 activation, is ineffective at inhibiting cell 
viability of HOXB13-overexpressing cells  
Downstream of IL6R signaling is the activation of STAT3, which was inhibited in 
HOXB13-expressing cells by treatment of the cells with Niclosamide.  Both MCF7 
HOXB13-overexpressing and BT474 HOXB13-KD cell models did not show decreased cell 
viability with increasing doses of Niclosamide (Figure 5.3).  
5.3 – NVP-BEZ-235, PI3K inhibitor, is effective at inhibiting HOXB13-specific cell 
viability 
We interrogated the PI3K/Akt pathway, by testing multiple PI3K inhibitors against 
our MCF7 HOXB13-overexpressing cell line panel.  Out of twelve drugs tested: AS-605240, 
BEZ235, GDC-0941, GSK1059615, IC-87114, LY294002, PI-103, PIK-90, TG100-115, 
TGX-221, XL147, and ZSTK474, the three drugs presenting the strongest HOXB13-
specific decrease in cell viability were further interrogated not only in the MCF7 HOXB13-
overexpressing cell line panel, but also in our BT474 HOXB13-KD cell line panel.  
Increasing doses of NVP-BEZ235 (64) induced HOXB13-specific decrease in cell viability 
for both MCF7 HOXB13-overexpressing cell lines as well as in the BT474-Scr line 
compared to vector control and KD cell lines respectively, making BEZ a promising drug 




Figure 5.3. Niclosamide does not significantly inhibit viability of HOXB13-
overexpressing cells in culture.  MTT cell viability after treatment with increasing doses of 
niclosamide in MCF7 HOXB13-overexpressing cells compared with MCF7 vector control 
























































Figure 5.4. BEZ235 significantly inhibits viability of HOXB13-overexpressing cells in 
culture. MTT cell viability after treatment with increasing doses of BEZ in MCF7 
HOXB13-overexpressing cells compared with MCF7 vector control and BT474-Scr cells 



























































Figure 5.5. LY294002 does not significantly inhibit viability of HOXB13-
overexpressing cells in culture.  MTT cell viability after treatment with increasing doses of 
BEZ in MCF7 HOXB13-overexpressing cells compared with MCF7 vector control and 


























































Figure 5.6. PI-103 does not significantly inhibit viability of HOXB13-overexpressing 
cells in culture.  MTT cell viability after treatment with increasing doses of BEZ in MCF7 
HOXB13-overexpressing cells compared with MCF7 vector control and BT474-Scr cells 


























































the MCF7 cell lines; however, this effect was not observed in the BT474 panel (Figure 5.5).  
PI-103 showed HOXB13-specific cell death at lower doses in BT474-Scr compared to 
BT474 HOXB13-KD cells, however; this effect was not replicated in our MCF7 HOXB13-
overexpressing panel (Figure 5.6). Following these studies, we decided to move forward with 
BEZ235 to verify inhibition of PI3K signaling in the HOXB13-expressing cells by western 
blot analysis. 
5.4 – NVP-BEZ-235 is effective at specifically inhibiting phospho-Akt activation in 
HOXB13-expressing cells 
We wanted to confirm the inhibition of IL6-pathway downstream effectors such as 
PI3K/Akt upon BEZ treatment in our HOXB13-expressing cells via western blot.  Due to 
the quick action of signaling molecules in the span of a few minutes to an hour, we 
employed 50 nM BEZ for 15-minute intervals up to an hour to determine its effects on both 
the overexpressing MCF7-HOXB13 and the BT474 HOXB13 KD cells.  In this time course 
experiment, we observed a greater inhibition of phospho-Akt in the HOXB13-
overexpressing MCF7 cells compared to vector, as well as in the BT474-Scr cells compared 
to the HOXB13 KD cells.  This result correlates with our previous observations in the cell 
viability assays (65-67) showing HOXB13-specific BEZ effect and previous western blots 
showing higher levels of p-AKT in the HOXB13-expressing cell lines (Figure 3.5b). 
Conclusions 
As with rapamycin, we investigated other IL6 pathway effectors by testing inhibitors 
against these effectors in our HOXB13-expressing cell line models in vitro.  We found TOC 
and BEZ to be ideal drug candidates that exhibit specificity against HOXB13-expressing 
cells.  However, because BEZ has already been tested extensively in breast cancer (65-67) 
and newer drugs targeting the PI3K pathway are a subject of great interest in the field (68), 
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we decided to move forward to test TOC in vivo.  Also, TOC has not been tested as a 
































Figure 5.7. PI3K/Akt pathway activation in HOXB13-overexpressing cells via IL6 is 
inhibited by BEZ235 in a time-course manner.  Western blot analysis of p-STAT3 
(Y705), p-AKT (S473), p-p70S6K, and p-4EBP1 in MCF7 HOXB13 and BT474 HOXB13-










In vivo targeting of the IL6 pathway 
in HOXB13-overexpressing breast cancer cell lines 
6.1 – Tocilizumab (TOC) and BEZ235, both alone and in combination, inhibit 
HOXB13-overexpressing TAMR xenograft tumor growth 
Based on the results of the Boyden chamber cell migration assay and the potent 
effects of TOC in this experiment, we embarked on studies with TOC to test inhibition of 
the IL6 pathway in vivo.  However, because targeting two vulnerable pathways in order to 
achieve greater effect was an attractive option for treatment, and due to the high PI3K/Akt 
activity observed in the MCF7 HOXB13-overexpressing cells, we investigated TOC alone 
and in combination with BEZ on xenografts of our panel of cells to test both for an additive 
or synergistic effect.  MCF7 HOXB13-overexpressing clone 2 xenografts were grown in 
NSG mice until tumors were palpable and then treated with vehicle control, TOC (100 μg 
i.p. 3 days per week), BEZ (30 mg/kg p.o. 5 days per week), or TOC and BEZ combined for 
6 weeks.  Although there were no changes in animal weight, BEZ-treated animals were 
noticeably more irritable.  Our results showed that each drug alone and in combination 
inhibited HOXB13-overexpressing tumor growth (Figure 6.1).  TOC alone had a marked 
effect, as did BEZ alone, however, the TOC and BEZ combination showed no 
improvement over BEZ alone, with no significant difference in tumor size in the 
TOC+BEZ groups. 
Due to its extensive use in breast cancer and toxicity in both pre-clinical and clinical 
studies, we decided to focus on TOC alone for our further in vivo investigations.  Because 
TOC was effective in inhibiting palpable HOXB13-overexpressing tumor growth, we tested 






Figure 6.1. Treatment of MCF7 HOXB13-overexpressing xenografts with TOC and 
BEZ, both alone and in combination inhibits palpable tumor growth.  Tumor growth 
of MCF7 HOXB13-overexpressing clone 2 cell subcutaneous xenografts in NSG mice 










































tumors grew to 100 mm3 and then treated with vehicle control or TOC (100 μg i.p. 3 days 
per week), with no changes in animal weight.  We observed decreased tumor growth and 
regression upon TOC treatment compared to vehicle control (Figure 6.2), confirming the 
ability of TOC to inhibit HOXB13-overexpressing established-tumor growth. 
To investigate the histological appearance of these tumors upon TOC treatment, we 
stained tumor sections with hematoxylin and eosin.  MCF7-vector control xenografts from 
our previous studies grow as a dense, encapsulated structure with very little stroma.  Sections 
from the xenografts from MCF7 HOXB13-overexpressing tumors were characterized by an 
increased stromal component, or desmoplastic response, seen as pink areas surrounding 
purple tumor cells, replicating the previously observed phenotype of the MCF7 HOXB13-
overexpressing tumors.  Upon TOC treatment, the increased stromal component was lost in 
the HOXB13-overexpressing tumors, showing inhibition of an increased stromal 
component and subsequent regression in HOXB13 tumor growth (Figure 6.3). 
While our MCF7 HOXB13-overexpressing cell lines serve as a useful model to 
address the conversion of a TAM-sensitive cell line to a TAMR cell line through 
introduction and overexpression of a single gene like HOXB13, we decided to investigate 
the effect of TOC on our BT474-Scr cell line, due to its ER-positivity, endogenous high 
HOXB13 expression levels, and TAMR phenotype.  Also, due to downregulation or 
abrogation of the IL6 pathway signaling via TOC treatment, we wanted to test if this action 
in our HOXB13-expressing cells could resensitize BT474-Scr to the effects of TAM.  
BT474-Scr xenografts were grown in NSG mice until tumors grew to 100 mm3 and then 
treated with vehicle control, TOC alone (100 μg i.p. 3 days per week), TAM alone (500 μg in 
peanut oil for slow release, s.c. 5 days per week), or TOC in combination with TAM, with no 






Figure 6.2. Treatment of MCF7 HOXB13-overexpressing xenografts with TOC 
inhibits established tumor growth.  Tumor growth of MCF7 HOXB13-overexpressing 
clone 2 cell subcutaneous xenografts in NSG mice treated with vehicle control or TOC upon 




































tumor growth as seen in prior studies by our group and others that the cells are TAMR.  
TOC-treated mice showed a highly significant reduction in tumor growth compared to 
vehicle control alone or TAM alone.  TOC in combination with TAM brought about even 
more significant reduction in tumor size; however, the difference between TOC alone and 
TOC+TAM was not statistically significant (Figure 6.4). 
To confirm if BT474-Scr tumor regression due to TOC treatment was specific for 
the presence of high levels of HOXB13, we treated BT474 HOXB13-KD clone 2 cell line 
xenografts with TOC and observed that whereas BT474-Scr xenografts with high levels of 
HOXB13 were sensitive to TOC, knockdown of HOXB13 in BT474 renders the xenografts 
insensitive to TOC (Figure 6.5). 
Conclusions 
 Our in vivo studies targeting the IL6 pathway showed TOC inhibition of HOXB13-
expressing tumor growth in both palpable and established MCF7 HOXB13-overexpressing 
xenografts, inhibiting the stromal response characteristic of the cell line xenografts.  We also 
observed tumor regression upon TOC treatment in established HOXB13-expressing BT474-
Scr xenografts, however, HOXB13 knockdown in BT474 resulted in loss of response of the 
cells to TOC, suggesting a key role for high levels of HOXB13-expression in the IL6R-












Figure 6.3. TOC treatment reversed stromal phenotype in MCF7 HOXB13-
overexpressing xenografts.  Hematoxylin and eosin-stained sections of MCF7 xenografts: 
MCF7-vector tumors grow as uniform sheets of cancer cells with little stromal component, 
whereas MCF7 HOXB13-overexpressing xenografts have significantly more stromal 


















Figure 6.4. Treatment of HOXB13-expressing BT474-Scr xenografts with TOC alone, 
TAM alone, or in combination inhibits established tumor growth.  Tumor growth of 
HOXB13-expressing BT474-Scr cell subcutaneous xenografts in NSG mice treated with 
















































Figure 6.5. Treatment of HOXB13-knockdown BT474-HOXB13-KD xenografts with 
TOC does not inhibit established tumor growth.  Tumor growth of HOXB13-
knockdown BT474-HOXB13-KD cell subcutaneous xenografts in NSG mice treated with 




































Many facets of the molecular mechanisms underlying TAMR are known; of note, the 
predictive value of HOXB13 as a clinical biomarker of TAMR.  In spite of this knowledge, 
for many years, no studies had examined the mechanisms by which HOXB13 contributed to 
disease aggression, specifically in TAM-R and metastatic recurrence.  Thus, an evaluation of 
HOXB13 function in TAM-R breast cancer was critical to identifying new therapeutic 
targets.  We conducted the first such examination of HOXB13 in breast cancer and showed 
its role in aggressive disease, consistent with clinical studies (33). 
For the first time, we assessed HOXB13 in distant metastatic tumors and confirmed 
that tumors from non-survivors had significantly higher mRNA levels of HOXB13 
compared with those from survivors, and HOXB13 expression significantly predicts disease 
recurrence and death from disease.  We also showed that HOXB13 promoted proliferation 
and TAMR in vivo, consistent with the association of HOXB13 expression with metastatic 
disease recurrence in patients despite treatment with TAM.  The experimental evidence and 
the increased stromal component in HOXB13-overexpressing tumor xenografts suggested 
HOXB13 promoted tumor formation and disease recurrence also by promoting other 
pathways, including proliferation and stromal recruitment. 
An extensive body of literature has emerged that supports cross-talk and cooperation 
between stromal cells and tumor cells at multiple levels such as: the soluble factors elicited 
by tumor cells and those in response by the stromal cells, changes in the extracellular matrix, 
and alterations in cell adhesion, which collectively lead to a microenvironment conducive to 
tumor progression (69, 70).  A major cell type that alters the tumor milieu is the stromal 
fibroblast.  To study the notable stromal recruitment visible in HOXB13 overexpressing 
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tumors, and to decipher the role of IL6–mediated pathways in this function, we modeled the 
in vivo conditions in tissue culture.  We showed the ability of normal murine and human 
fibroblasts to migrate toward conditioned medium from HOXB13-overexpressing tumor 
cells, but not from vector control cells; and that the action was abrogated by pre-treating the 
fibroblasts with anti-IL6R antibody.  Although this approach replicated the recruitment of 
naïve fibroblasts to the tumor site by IL6 secreted by tumor cells, it would also be important 
to study, in the future, the molecular and biological differences between cancer-associated-
fibroblasts (CAF) existing in the tumors and in normal fibroblasts in the breast, and how 
CAF action relates to hormone resistance mediated by HOXB13. 
In our studies, we confirmed HOXB13-directed transcriptional activation of IL6, a 
common mediator of stromal recruitment IL6 is an activator of the AKT pathway, and that 
this activation is suppressed by mTOR inhibitors (55, 71).  We specifically showed that the 
mTOR inhibitor rapamycin can suppress the proliferation of ER-positive, HOXB13-
expressing cells in vitro and in vivo, alone or in combination with TAM.  This work led us to 
conclude that HOXB13 expression makes the cells dependent on mTOR-mediated pathways 
for this proliferation.  In spite of these results, these pathways needed to be more fully 
defined to identify other effective, potential mechanisms of HOXB13-mediated TAMR.   
As with rapamycin in the aforementioned studies, further investigation for effective 
targeted treatment against HOXB13-mediated TAMR was conducted via microarray analysis 
of our BT474 HOXB13-KD cell line panel searching for novel molecules that correlate with 
HOXB13 expression.  Further, we interrogated inhibitors against other effectors of the IL6 
pathway such as IL6R, Stat3, and PI3K/Akt in vitro and in vivo against our HOXB13-
expressing cell line panels. 
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We present the HOXB13-specific effects of the anti-IL6R antibody tocilizumab 
(TOC), a drug widely used to treat rheumatoid arthritis, but not yet considered as a 
treatment for breast cancer.  Because the effects of rapamycin are published, we will discuss 
the effects of TOC alone.  Our studies show that although TOC does not inhibit HOXB13-
specific cell viability in vitro, it abrogates in vitro fibroblast migration to HOXB13-expressing 
conditioned media compared to vector and HOXB13-knockdown controls.  Of note, our in 
vivo studies highlight the ability of TOC to inhibit both palpable and established tumor 
growth of both our MCF7 and BT474 HOXB13-expressing models, significantly reducing 
the stromal desmoplastic response typical of aggressive tumors (72) and characteristic of our 
HOXB13-overexpressing cell line model.  Knockdown of HOXB13 in our BT474 cell line 
rendered xenografts insensitive to TOC treatment, thus confirming the specificity of TOC 
treatment against HOXB13-expressing cells.  These results present tocilizumab as a 
promising drug candidate specifically targeting HOXB13-overexpressing TAMR breast 
cancer growth. 
We addressed the importance of HOXB13-mediated overexpression of IL6 as a 
paracrine means of activating tumor associated stroma by establishing IL6-induced fibroblast 
migration and direct HOXB13 binding of the IL6 promoter; however, more studies are 
necessary to answer more specifics regarding this stroma-tumor interaction.  A recent study 
has shown that cancer-associated fibroblasts (CAFs) can induce TAMR in the luminal (ER-
positive) subtype of breast cancer via IL6 secretion and subsequent IL6 pathway signaling in 
the associated tumor cells (73), underlining the importance of the stromal component in 
TAMR.  It would be interesting to investigate if HOXB13 may play a role in this model of 
TAMR, especially with regard to HOXB13 levels in the tumor cells before and after CAF 
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exposure, as our HOXB13 overexpressing cell line models are also characteristic of TAMR, 
stromal infiltration, and IL6 expression. 
 Our work provides evidence for the novel use of TOC for the treatment of ER-
positive breast tumors with high levels of HOXB13 expression at initial diagnosis.  Further 
pre-clinical in vivo experiments in other established TAMR or HOXB13-overexpressing cell 
lines in combination with TAM and/or AIs would be useful to confirm the specificity of 
TOC on HOXB13-expressing TAMR models.  For the first time, TOC has been shown to 
inhibit in vitro and in vivo HOXB13-expressing tumor growth and thus is a promising 
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